Skip to main content
Clinical Trials/KCT0012407
KCT0012407Active, not recruitingNot Applicable

MR Contrast Media Change for Reduction of Adverse Drug Reaction

Asan Medical Center0 sites166 target enrollmentStarted: August 24, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
166

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Primary Purpose
Treatment

Eligibility Criteria

Ages
18(Year) to 80(Year) (—)
Sex
All

Inclusion Criteria

  • Patients aged 18 to 80 years.
  • Patients with a history of GBCA-related adverse drug reactions, classified as mild or moderate according to Korean clinical practice guidelines
  • Patients who are able to provide relevant information, including the type of GBCA associated with the previous reaction and the type and severity of the previous GBCA-related ADR.
  • Patients with a medical indication for contrast-enhanced MRI.

Exclusion Criteria

  • Patients who have experienced adverse reactions to two or more different GBCAs.
  • Patients whose previous GBCA-related adverse reaction was caused by gadoxetate disodium.
  • Patients who do not wish to receive premedication.
  • Patients who underwent contrast-enhanced CT or MRI within 24 hours before screening.
  • Patients for whom a specific GBCA has been designated by the Department of Allergy and Immunology.
  • Patients with a history of severe GBCA-related adverse reactions, including anaphylaxis, as defined by Korean clinical practice guidelines.
  • Patients requiring contrast agent administration through a central venous catheter.

Investigators

Similar Trials